NYSEAMERICAN:NAVB - Navidea Biopharmaceuticals Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$0.24 +0.01 (+4.35 %)
(As of 05/20/2018 04:00 PM ET)
Previous Close$0.24
Today's Range$0.2250 - $0.2450
52-Week Range$0.21 - $0.68
Volume241,034 shs
Average Volume302,216 shs
Market Capitalization$62.36 million
P/E RatioN/A
Dividend YieldN/A
Beta-0.78

About Navidea Biopharmaceuticals (NYSEAMERICAN:NAVB)

Navidea Biopharmaceuticals logoNavidea Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. The company operates in two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages; and NAV4694, a fluorine-18 labeled positron emission tomography imaging agent for use as an aid in the imaging and evaluation of patients with signs or symptoms of Alzheimers disease and mild cognitive impairment. It is also developing NAV5001, an iodine-123 labeled single photon emission computed tomography imaging agent that is used as an aid in the diagnosis of Parkinson's disease and other movement disorders with potential use as a diagnostic aid in dementia; diagnostic substances, including technetium 99m tilmanocept and other diagnostic applications of its Manocept platform; and therapeutic development programs, such as therapeutic applications of its Manocept platform, as well as various development programs. The company was formerly known as Neoprobe Corporation and changed its name to Navidea Biopharmaceuticals, Inc. in January 2012. Navidea Biopharmaceuticals, Inc. was founded in 1983 and is headquartered in Dublin, Ohio.

Receive NAVB News and Ratings via Email

Sign-up to receive the latest news and ratings for NAVB and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryHealth Care Equipment
SectorMedical
SymbolNYSEAMERICAN:NAVB
CUSIP63937X10
Phone+1-614-7937500

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net Margins-688.85%
Return on Equity-38.60%
Return on Assets-25.48%

Miscellaneous

EmployeesN/A
Outstanding Shares162,960,000

Navidea Biopharmaceuticals (NYSEAMERICAN:NAVB) Frequently Asked Questions

What is Navidea Biopharmaceuticals' stock symbol?

Navidea Biopharmaceuticals trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "NAVB."

How were Navidea Biopharmaceuticals' earnings last quarter?

Navidea Biopharmaceuticals, Inc. (NYSEAMERICAN:NAVB) issued its quarterly earnings results on Tuesday, May, 8th. The biopharmaceutical company reported ($0.04) earnings per share for the quarter. The biopharmaceutical company had revenue of $0.28 million for the quarter. Navidea Biopharmaceuticals had a negative net margin of 688.85% and a negative return on equity of 38.60%. View Navidea Biopharmaceuticals' Earnings History.

Are investors shorting Navidea Biopharmaceuticals?

Navidea Biopharmaceuticals saw a increase in short interest during the month of April. As of April 30th, there was short interest totalling 4,192,104 shares, an increase of 1.5% from the April 13th total of 4,131,039 shares. Based on an average daily trading volume, of 360,457 shares, the short-interest ratio is presently 11.6 days. Approximately 2.7% of the company's shares are sold short.

Who are some of Navidea Biopharmaceuticals' key competitors?

Who are Navidea Biopharmaceuticals' key executives?

Navidea Biopharmaceuticals' management team includes the folowing people:
  • Dr. Michael M. Goldberg, CEO, Pres & Director (Age 59)
  • Mr. Jed A. Latkin, CFO, COO, Sec., Treasurer & Principal Accounting officer (Age 44)
  • Dr. Frederick O. Cope Ph.D., F.A.C.N., C.N.S., Chief Scientific Officer & Sr. VP (Age 71)
  • Mr. William J. Regan, Chief Compliance Officer and Sr. VP of Global Regulatory Affairs & Quality (Age 66)
  • Ms. Sharon Correia, Sr. Director of Corp. Communications

Has Navidea Biopharmaceuticals been receiving favorable news coverage?

Media coverage about NAVB stock has been trending somewhat positive on Sunday, Accern reports. The research firm identifies positive and negative media coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Navidea Biopharmaceuticals earned a media sentiment score of 0.09 on Accern's scale. They also gave press coverage about the biopharmaceutical company an impact score of 45.88 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company's share price in the near term.

How do I buy shares of Navidea Biopharmaceuticals?

Shares of NAVB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Navidea Biopharmaceuticals' stock price today?

One share of NAVB stock can currently be purchased for approximately $0.24.

How big of a company is Navidea Biopharmaceuticals?

Navidea Biopharmaceuticals has a market capitalization of $62.36 million.

How can I contact Navidea Biopharmaceuticals?

Navidea Biopharmaceuticals' mailing address is 4995 Bradenton Ave Ste 240, DUBLIN, OH 43017-3552, United States. The biopharmaceutical company can be reached via phone at +1-614-7937500.


MarketBeat Community Rating for Navidea Biopharmaceuticals (NAVB)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  121 (Vote Outperform)
Underperform Votes:  107 (Vote Underperform)
Total Votes:  228
MarketBeat's community ratings are surveys of what our community members think about Navidea Biopharmaceuticals and other stocks. Vote "Outperform" if you believe NAVB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NAVB will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Navidea Biopharmaceuticals (NYSEAMERICAN:NAVB) Analyst Ratings History

DateBrokerageActionRatingPrice TargetDetails
(Data available from 5/20/2016 forward)

Earnings

Navidea Biopharmaceuticals (NYSEAMERICAN:NAVB) Earnings History and Estimates Chart

Earnings by Quarter for Navidea Biopharmaceuticals (NYSEAMERICAN:NAVB)

Navidea Biopharmaceuticals (NYSEAMERICAN NAVB) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/8/2018Q1 2018($0.04)$0.28 millionViewN/AView Earnings Details
3/8/2018Q4 2017($0.03)$0.40 millionViewN/AView Earnings Details
11/7/2017Q3 2017($0.01)$0.22 millionViewN/AView Earnings Details
8/8/2017Q2 2017($0.02)$0.61 millionViewListenView Earnings Details
5/9/2017Q1 2017($0.01)$0.58 millionViewN/AView Earnings Details
3/29/2017Q4 2016($0.02)$3.36 millionViewN/AView Earnings Details
8/4/2016Q216($0.03)($0.04)$5.24 million$5.40 millionViewN/AView Earnings Details
5/17/2016Q1($0.03)($0.02)$4.63 million$4.70 millionViewListenView Earnings Details
3/23/2016Q415($0.04)($0.02)$3.70 million$4.00 millionViewListenView Earnings Details
11/4/2015Q315($0.04)($0.05)$2.40 million$3.98 millionViewListenView Earnings Details
7/30/2015Q215($0.04)($0.06)$2.18 million$2.90 millionViewListenView Earnings Details
5/12/2015Q115($0.03)($0.05)$3.30 million$2.10 millionViewListenView Earnings Details
3/5/2015($0.04)($0.05)$1.95 million$2.20 millionViewN/AView Earnings Details
3/5/2015($0.04)($0.05)$1.95 million$2.20 millionViewN/AView Earnings Details
3/5/2015Q414($0.05)($0.05)$2.10 million$2.20 millionViewListenView Earnings Details
11/6/2014Q314($0.06)($0.05)$1.54 million$2.30 millionViewListenView Earnings Details
8/6/2014Q214($0.07)($0.07)$1.05 million$1.05 millionViewListenView Earnings Details
5/7/2014Q114($0.10)($0.06)$0.90 million$0.7520 millionViewListenView Earnings Details
3/6/2014Q413($0.08)($0.10)$0.74 million$0.5350 millionViewListenView Earnings Details
11/6/2013Q313($0.08)$0.09$0.97 million$0.40 millionViewListenView Earnings Details
8/7/2013Q2 2013($0.07)($0.09)$0.55 million$0.20 millionViewN/AView Earnings Details
5/8/2013Q1 2013($0.07)($0.06)$0.02 millionViewN/AView Earnings Details
3/6/2013Q4 2012($0.08)($0.08)ViewN/AView Earnings Details
11/8/2012Q312$0.21($0.09)ViewN/AView Earnings Details
8/6/2012Q2 2012($0.06)($0.06)ViewN/AView Earnings Details
5/2/2012Q1 2012($0.07)($0.07)ViewN/AView Earnings Details
2/29/2012Q4 2011($0.05)($0.08)ViewN/AView Earnings Details
10/26/2011Q3 2011($0.03)($0.07)ViewN/AView Earnings Details
7/27/2011Q2 2011($0.02)($0.02)ViewN/AView Earnings Details
5/9/2011Q1 2011($0.02)($0.05)ViewN/AView Earnings Details
3/7/2011Q4 2010($0.03)($0.03)ViewN/AView Earnings Details
11/10/2010Q3 2010($0.01)($0.03)ViewN/AView Earnings Details
8/9/2010Q2 2010($0.02)($0.02)ViewN/AView Earnings Details
4/28/2010Q1 2010($0.01)($0.03)ViewN/AView Earnings Details
11/2/2009Q3 2009($0.31)($0.10)ViewN/AView Earnings Details
8/11/2009Q2 2009($0.02)($0.02)ViewN/AView Earnings Details
5/6/2009Q1 2009$0.01ViewN/AView Earnings Details
3/10/2009Q4 2008($0.03)($0.02)ViewN/AView Earnings Details
11/5/2008Q3 2008($0.02)($0.03)ViewN/AView Earnings Details
8/4/2008Q2 2008($0.03)($0.02)ViewN/AView Earnings Details
5/1/2008Q1 2008($0.01)($0.02)ViewN/AView Earnings Details
3/19/2008Q4 2007($0.01)($0.02)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Navidea Biopharmaceuticals (NYSEAMERICAN:NAVB) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Navidea Biopharmaceuticals (NYSEAMERICAN NAVB) Insider Trading and Institutional Ownership History

Insider Trading History for Navidea Biopharmaceuticals (NYSEAMERICAN:NAVB)
Institutional Ownership by Quarter for Navidea Biopharmaceuticals (NYSEAMERICAN:NAVB)

Navidea Biopharmaceuticals (NYSEAMERICAN NAVB) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
6/29/2017William J ReganSVPBuy20,000$0.53$10,600.00172,977View SEC Filing  
5/30/2017Jed LatkinCFOBuy7,600$0.44$3,344.0050,159View SEC Filing  
5/22/2017Jed LatkinCFOBuy25,359$0.45$11,411.5531,359View SEC Filing  
12/1/2015Brent L LarsonCFOSell12,500$1.50$18,750.00222,237View SEC Filing  
10/1/2015Brent L LarsonCFOSell12,500$2.27$28,375.00247,237View SEC Filing  
9/1/2015Brent L LarsonCFOSell12,500$1.88$23,500.00259,737View SEC Filing  
6/1/2015Brent L LarsonCFOSell12,500$1.24$15,500.00View SEC Filing  
5/29/2015Gordon A TroupDirectorBuy10,000$1.31$13,100.00View SEC Filing  
11/14/2014Michael M GoldbergDirectorBuy100,000$1.08$108,000.00View SEC Filing  
11/10/2014Brendan A FordDirectorBuy10,000$1.03$10,300.00View SEC Filing  
5/9/2014Mark Jerome PykettCEOBuy10,000$1.34$13,400.00292,674View SEC Filing  
3/10/2014Brent LarsonCFOSell41,500$1.96$81,340.00319,184View SEC Filing  
3/10/2014Frederick CopeSVPSell15,000$1.96$29,400.0075,814View SEC Filing  
3/10/2014Mark Jerome PykettCEOSell120,000$1.96$235,200.00282,674View SEC Filing  
11/8/2013Brendan FordDirectorBuy20,000$1.45$29,000.00139,250View SEC Filing  
11/8/2013Brent LarsonCFOBuy5,000$1.39$6,950.00287,304View SEC Filing  
11/8/2013Frederick CopeSVPBuy3,500$1.43$5,005.0090,814View SEC Filing  
11/8/2013Mark Jerome PykettCEOBuy10,900$1.35$14,715.00402,674View SEC Filing  
3/15/2013Gordon A TroupDirectorBuy7,000$2.70$18,900.00View SEC Filing  
3/15/2013Mark Jerome PykettCEOBuy1,850$2.70$4,995.00View SEC Filing  
3/15/2013Thomas H TulipEVPBuy17,500$2.82$49,350.00View SEC Filing  
3/15/2013William J ReganSVPBuy5,000$2.71$13,550.00View SEC Filing  
9/14/2012Thomas H TulipEVPBuy15,000$2.70$40,500.00View SEC Filing  
9/12/2012Brendan A FordDirectorBuy5,000$2.64$13,200.00View SEC Filing  
9/11/2012Mark Jerome PykettCEOBuy4,000$2.64$10,560.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Navidea Biopharmaceuticals (NYSEAMERICAN NAVB) News Headlines

Source:
DateHeadline
Edited Transcript of NAVB earnings conference call or presentation 9-May-18 12:30pm GMTEdited Transcript of NAVB earnings conference call or presentation 9-May-18 12:30pm GMT
finance.yahoo.com - May 10 at 10:06 AM
Navidea Biopharmaceuticals, Inc. (NAVB) Sees Large Increase in Short InterestNavidea Biopharmaceuticals, Inc. (NAVB) Sees Large Increase in Short Interest
www.americanbankingnews.com - May 9 at 5:24 PM
Navidea Biopharmaceuticals (NAVB) CEO Michael Goldberg on Q1 2018 Results - Earnings Call TranscriptNavidea Biopharmaceuticals' (NAVB) CEO Michael Goldberg on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 9 at 4:10 PM
Navidea Biopharmaceuticals Reports First Quarter 2018 Financial ResultsNavidea Biopharmaceuticals Reports First Quarter 2018 Financial Results
finance.yahoo.com - May 9 at 9:54 AM
Navidea: 1Q Earnings SnapshotNavidea: 1Q Earnings Snapshot
finance.yahoo.com - May 9 at 9:54 AM
Navidea Biopharmaceuticals to Present at 3rd Annual Disruptive Growth & Healthcare Conference Hosted by RHK Capital and ReedSmithNavidea Biopharmaceuticals to Present at 3rd Annual Disruptive Growth & Healthcare Conference Hosted by RHK Capital and ReedSmith
finance.yahoo.com - May 8 at 9:49 AM
Navidea Biopharmaceuticals Schedules First Quarter 2018 Earnings Conference Call and Business UpdateNavidea Biopharmaceuticals Schedules First Quarter 2018 Earnings Conference Call and Business Update
finance.yahoo.com - May 2 at 4:07 PM
Navidea Biopharmaceuticals, Inc. (NAVB) Short Interest Down 0.1% in AprilNavidea Biopharmaceuticals, Inc. (NAVB) Short Interest Down 0.1% in April
www.americanbankingnews.com - April 26 at 1:14 AM
Navidea Biopharmaceuticals to Present at 2nd Annual NASH SummitNavidea Biopharmaceuticals to Present at 2nd Annual NASH Summit
finance.yahoo.com - April 24 at 9:55 AM
Navidea signs deal to sublicense NAV4694 worldwide development rightsNavidea signs deal to sublicense NAV4694 worldwide development rights
seekingalpha.com - April 16 at 9:56 AM
Navidea Biopharmaceuticals, Inc. (NAVB) Short Interest UpdateNavidea Biopharmaceuticals, Inc. (NAVB) Short Interest Update
www.americanbankingnews.com - April 11 at 2:04 AM
Navidea Biopharmaceuticals (NAVB) Rating Increased to Hold at ValuEngineNavidea Biopharmaceuticals (NAVB) Rating Increased to Hold at ValuEngine
www.americanbankingnews.com - April 9 at 4:05 PM
Active-Investors: Wired News - EMA to Review Regenerons Marketing Authorization Application for CemiplimabActive-Investors: Wired News - EMA to Review Regeneron's Marketing Authorization Application for Cemiplimab
www.finanznachrichten.de - April 5 at 8:38 AM
Navidea Biopharmaceuticals Schedules Conference Call to Discuss Future Outlook and Outcomes of Court TrialNavidea Biopharmaceuticals Schedules Conference Call to Discuss Future Outlook and Outcomes of Court Trial
finance.yahoo.com - April 3 at 4:13 PM
Navidea Biopharmaceuticals Inc (NAVB) Sees Large Decrease in Short InterestNavidea Biopharmaceuticals Inc (NAVB) Sees Large Decrease in Short Interest
www.americanbankingnews.com - March 27 at 1:54 AM
Edited Transcript of NAVB earnings conference call or presentation 8-Mar-18 9:30pm GMTEdited Transcript of NAVB earnings conference call or presentation 8-Mar-18 9:30pm GMT
finance.yahoo.com - March 23 at 9:36 AM
Navidea Biopharmaceuticals to Present at 25th Annual Future Leaders in the Biotech IndustryNavidea Biopharmaceuticals to Present at 25th Annual Future Leaders in the Biotech Industry
finance.yahoo.com - March 23 at 9:36 AM
Annual Future Leaders in the Biotech Industry - Business Wire (press release)Annual Future Leaders in the Biotech Industry - Business Wire (press release)
www.businesswire.com - March 16 at 10:57 AM
Navidea Biopharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results - Business Wire (press release)Navidea Biopharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results - Business Wire (press release)
www.businesswire.com - March 10 at 4:14 PM
Short Interest in Navidea Biopharmaceuticals Inc (NAVB) Expands By 0.2%Short Interest in Navidea Biopharmaceuticals Inc (NAVB) Expands By 0.2%
www.americanbankingnews.com - March 10 at 2:52 AM
Navidea Biopharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial ResultsNavidea Biopharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results
finance.yahoo.com - March 9 at 11:54 AM
Navidea Biopharmaceuticals Schedules Fourth Quarter and Full Year 2017 Earnings Conference Call and Business UpdateNavidea Biopharmaceuticals Schedules Fourth Quarter and Full Year 2017 Earnings Conference Call and Business Update
finance.yahoo.com - March 1 at 10:02 AM
Navidea Biopharmaceuticals Inc (NAVB) Short Interest UpdateNavidea Biopharmaceuticals Inc (NAVB) Short Interest Update
www.americanbankingnews.com - February 9 at 8:28 PM
Navidea to Host Moderated Q&A Webcast with Management - Business Wire (press release)Navidea to Host Moderated Q&A Webcast with Management - Business Wire (press release)
www.businesswire.com - February 2 at 5:57 AM
Navidea to Host Moderated Q&A Webcast with ManagementNavidea to Host Moderated Q&A Webcast with Management
finance.yahoo.com - February 2 at 5:57 AM
Navidea Biopharmaceuticals Inc (NAVB) Short Interest Down 2.1% in JanuaryNavidea Biopharmaceuticals Inc (NAVB) Short Interest Down 2.1% in January
www.americanbankingnews.com - January 25 at 1:33 AM
Short Interest in Navidea Biopharmaceuticals Inc (NAVB) Decreases By 12.0%Short Interest in Navidea Biopharmaceuticals Inc (NAVB) Decreases By 12.0%
www.americanbankingnews.com - January 11 at 1:22 AM
Navidea Biopharmaceuticals, Inc. :NAVB-US: Earnings Analysis: Q3, 2017 By the Numbers : January 1, 2018Navidea Biopharmaceuticals, Inc. :NAVB-US: Earnings Analysis: Q3, 2017 By the Numbers : January 1, 2018
finance.yahoo.com - January 1 at 9:28 AM
Navidea Biopharmaceuticals Inc (NAVB) Sees Significant Increase in Short InterestNavidea Biopharmaceuticals Inc (NAVB) Sees Significant Increase in Short Interest
www.americanbankingnews.com - December 27 at 6:38 PM
Navidea Biopharmaceuticals to Present at Biotech Showcase 2018Navidea Biopharmaceuticals to Present at Biotech Showcase 2018
finance.yahoo.com - December 19 at 5:18 PM
Navidea Biopharmaceuticals Inc (NAVB) Short Interest Up 3.6% in NovemberNavidea Biopharmaceuticals Inc (NAVB) Short Interest Up 3.6% in November
www.americanbankingnews.com - November 27 at 8:24 PM
Navidea Biopharmaceuticals to Present at LD Micro 10 - Business Wire (press release)Navidea Biopharmaceuticals to Present at LD Micro 10 - Business Wire (press release)
www.businesswire.com - November 21 at 8:31 AM
Navidea Biopharmaceuticals to Present at LD Micro 10th Annual Main EventNavidea Biopharmaceuticals to Present at LD Micro 10th Annual Main Event
finance.yahoo.com - November 21 at 8:31 AM
Navidea Biopharmaceuticals to Present at LD Micro 10th Annual Main EventNavidea Biopharmaceuticals to Present at LD Micro 10th Annual Main Event
finance.yahoo.com - November 21 at 8:31 AM

SEC Filings

Navidea Biopharmaceuticals (NYSEAMERICAN:NAVB) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Navidea Biopharmaceuticals (NYSEAMERICAN:NAVB) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Navidea Biopharmaceuticals (NYSEAMERICAN NAVB) Stock Chart for Sunday, May, 20, 2018

Loading chart…

This page was last updated on 5/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.